Parse Biosciences Secures $50M to Unravel Single-Cell Secrets and Power Medical Breakthroughs

Parse Biosciences Secures $50M Boost to Power Single Cell Sequencing Advancements

Seattle-based life sciences company Parse Biosciences has secured a $50 million Series C funding round, propelling its total funding past the $100 million mark.

The investment will fuel the company’s mission to revolutionize human health and scientific research through innovative single-cell sequencing technology.

Soleus Capital led the round, with participation from a mix of new and existing investors:

Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital.

Horizon Technology Finance Corporation further bolstered the company’s resources with a debt facility.

Parse’s cutting-edge technology empowers researchers to delve deeper into the intricate world of single cells.

This granular approach, enabled by Parse’s user-friendly platform, is unlocking groundbreaking discoveries in diverse fields like cancer treatment, tissue regeneration, stem cell therapies, and immune system exploration.

The company’s comprehensive single-cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, and various fixation and analysis solutions, is now available in a growing number of international markets.

Researchers in Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea are now leveraging Parse’s tools to unlock the secrets hidden within individual cells.

Founded in 2018 based on technology developed at the University of Washington, Parse has already gained the trust of over 1,000 labs worldwide.

This impressive adoption rate testifies to the company’s commitment to democratizing access to single-cell sequencing and its potential to revolutionize scientific understanding at the cellular level.

With this fresh injection of capital, Parse is poised to further expand its product portfolio and commercial reach, paving the way for even more groundbreaking discoveries in the years to come.

Conclusion:

$50M Series C funding round for Parse Biosciences.

Funds to fuel product expansion and global reach.

Single-cell sequencing technology empowering research across diverse fields.

Over 1,000 labs worldwide utilizing Parse’s solutions.

Company on track to further revolutionize cellular-level research.